🇺🇸 FDA
Patent

US 9233973

Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same

granted A61KA61K31/165A61K31/167

Quick answer

US patent 9233973 (Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/165, A61K31/167, A61K31/192, A61K31/195